291 related articles for article (PubMed ID: 10211134)
1. Glutamatergic aspects of schizophrenia.
Tamminga C
Br J Psychiatry Suppl; 1999; (37):12-5. PubMed ID: 10211134
[TBL] [Abstract][Full Text] [Related]
2. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
[TBL] [Abstract][Full Text] [Related]
3. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
Javitt DC
Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
[TBL] [Abstract][Full Text] [Related]
4. Glutamate pharmacology and the treatment of schizophrenia: current status and future directions.
Tamminga CA; Holcomb HH; Gao XM; Lahti AC
Int Clin Psychopharmacol; 1995 Sep; 10 Suppl 3():29-37. PubMed ID: 8866763
[TBL] [Abstract][Full Text] [Related]
5. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors.
Bubeníková-Valesová V; Horácek J; Vrajová M; Höschl C
Neurosci Biobehav Rev; 2008 Jul; 32(5):1014-23. PubMed ID: 18471877
[TBL] [Abstract][Full Text] [Related]
6. Rapid cortico-limbic alterations in AMPA receptor densities after administration of PCP: implications for schizophrenia.
Zavitsanou K; Nguyen V; Newell K; Ballantyne P; Huang XF
J Chem Neuroanat; 2008 Oct; 36(2):71-6. PubMed ID: 18640263
[TBL] [Abstract][Full Text] [Related]
7. The acute effects of NMDA antagonism: from the rodent to the human brain.
Gunduz-Bruce H
Brain Res Rev; 2009 May; 60(2):279-86. PubMed ID: 18703087
[TBL] [Abstract][Full Text] [Related]
8. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.
Pietraszek M
Pol J Pharmacol; 2003; 55(2):133-54. PubMed ID: 12926541
[TBL] [Abstract][Full Text] [Related]
9. Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia.
Holcomb HH; Lahti AC; Medoff DR; Cullen T; Tamminga CA
Neuropsychopharmacology; 2005 Dec; 30(12):2275-82. PubMed ID: 16034443
[TBL] [Abstract][Full Text] [Related]
10. [Glutamatergic neurotransmission in schizophrenics].
Bleich S; Bleich K; Wiltfang J; Maler JM; Kornhuber J
Fortschr Neurol Psychiatr; 2001 Sep; 69 Suppl 2():S56-61. PubMed ID: 11533851
[TBL] [Abstract][Full Text] [Related]
11. N-methyl-D-aspartate antagonists as drug models of schizophrenia: a surprising link to tobacco smoking.
Domino EF; Mirzoyan D; Tsukada H
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Aug; 28(5):801-11. PubMed ID: 15363604
[TBL] [Abstract][Full Text] [Related]
12. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
Marek GJ; Behl B; Bespalov AY; Gross G; Lee Y; Schoemaker H
Mol Pharmacol; 2010 Mar; 77(3):317-26. PubMed ID: 19933774
[TBL] [Abstract][Full Text] [Related]
13. N-methyl-D-aspartate autoreceptors respond to low and high agonist concentrations by facilitating, respectively, exocytosis and carrier-mediated release of glutamate in rat hippocampus.
Luccini E; Musante V; Neri E; Raiteri M; Pittaluga A
J Neurosci Res; 2007 Dec; 85(16):3657-65. PubMed ID: 17671992
[TBL] [Abstract][Full Text] [Related]
14. Sustained metabolic inhibition induces an increase in the content and phosphorylation of the NR2B subunit of N-methyl-D-aspartate receptors and a decrease in glutamate transport in the rat hippocampus in vivo.
Camacho A; Montiel T; Massieu L
Neuroscience; 2007 Mar; 145(3):873-86. PubMed ID: 17331654
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation.
Laruelle M; Frankle WG; Narendran R; Kegeles LS; Abi-Dargham A
Clin Ther; 2005; 27 Suppl A():S16-24. PubMed ID: 16198197
[TBL] [Abstract][Full Text] [Related]
16. [Glutamate hypothesis of schizophrenia and targets for new antipsychotic drugs].
Hashimoto K; Iyo M
Nihon Shinkei Seishin Yakurigaku Zasshi; 2002 Feb; 22(1):3-13. PubMed ID: 11917507
[TBL] [Abstract][Full Text] [Related]
17. Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder.
Woo TU; Walsh JP; Benes FM
Arch Gen Psychiatry; 2004 Jul; 61(7):649-57. PubMed ID: 15237077
[TBL] [Abstract][Full Text] [Related]
18. NMDA receptors and schizophrenia.
Kristiansen LV; Huerta I; Beneyto M; Meador-Woodruff JH
Curr Opin Pharmacol; 2007 Feb; 7(1):48-55. PubMed ID: 17097347
[TBL] [Abstract][Full Text] [Related]
19. A glutamatergic deficiency model of schizophrenia.
Carlsson A; Hansson LO; Waters N; Carlsson ML
Br J Psychiatry Suppl; 1999; (37):2-6. PubMed ID: 10211132
[TBL] [Abstract][Full Text] [Related]
20. Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis.
Heath PR; Shaw PJ
Muscle Nerve; 2002 Oct; 26(4):438-58. PubMed ID: 12362409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
